General Information
Age Group
AdultsStatus
RecruitingProtocol Number
NCT03138512Background Information
The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney
Offered At
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
- Kidney tumor has been completely resected 4 to 12 weeks prior to randomization
- Pathologic TNM staging meeting one of the following: pT2a, G3 or G4, N0 M0; pT2b, G any, N0 M0; pT3, G any, N0 M0; pT4, G any, N0 M0; pT any, G any, N1 M0
- Post-nephrectomy tumor shows RCC with a predominantly clear cell histology, including participants with sarcomatoid features
- Additional eligibility in protocol
Ineligibility Information
- Participants with an active known or suspected autoimmune disease
- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Any severe or serious, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
- Participants with a condition requiring systemic treatment with corticosteroids
- Additional ineligibility in protocol
For more information go to https://clinicaltrials.gov/ct2/show/NCT03138512